血液衍生生物标记市场：按类型、疾病、应用和地区划分

2026年，血液衍生生物标记市场规模估计为85亿美元，预计2033年将达到165亿美元。预计2026年至2033年，该市场将以7%的复合年增长率成长。

生物标誌物，或称为生物标记物，是指能够反映细胞或生物体在特定时刻所发生状态的各种指标。血液来源的生物标记在提案新的诊断方法和治疗方法非常有效。血液来源的生物标记具有显着的优势，即高效且经济。

市场动态

全球血液衍生生物标记市场的主要企业正致力于采取产品发布、合作和资金筹措等成长策略，预计这些策略将在预测期内推动市场成长。例如，2020年9月，总部位于西好莱坞的肿瘤公司ONCOtracker, Inc.与为全球临床医生和实验室技术人员提供专业诊断产品的The Binding Site Group Ltd.宣布，双方已达成一项全球独家许可和合作协议，共同开发一种用于测量sBCMA的新型临床检测方法。 sBCMA是一种新型血液衍生生物标记物，可望用于后续观察和预测常见血液癌症（包括多发性骨髓瘤（MM）和慢性淋巴性白血病（CLL））及其他相关疾病患者的预后。此外，例如，2021年4月，女性健康公司Sera Prognostics获得了1亿美元的E轮资金筹措，用于加速其PreTRM检测的商业化进程，该检测用于评估早产风险。 PreTRM 检测是一种经过临床检验且市售的血液生物标记检测，能够对无症状单胎妊娠的自发性早产风险进行早期、准确和个人化的预测。

本报告的主要特点

• 本报告对全球血液衍生生物标记市场进行了详细分析，包括市场规模和预测期（2026-2033 年）的复合年增长率，以 2025 年为基准年。
• 此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本节根据以下参数，对全球血液衍生生物标记市场的主要企业进行介绍：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球血液衍生生物标记市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球血液衍生生物标记市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
• 影响分析
• 市场趋势
• 主要进展
• 产品核准
• 合作关係、併购
• 监理情势
• PEST分析
• 波特五力分析
• 流行病学
• 固体管道分析

第四章：血液衍生生物标记市场：按类型划分（2026-2033 年）

• 用于筛检的生物标记
• 诊断生物标记
• 其他的

第五章：血液衍生生物标记市场：依疾病分类（2026-2033 年）

• 癌症
• 神经系统疾病
• 其他的

第六章：血液衍生生物标记市场：按应用领域划分（2026-2033 年）

• 诊断
• 药物发现
• 个人化医疗

第七章 血液衍生生物标记市场：按地区划分（2026-2033 年）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • 波湾合作理事会（GCC）国家
  • 以色列
  • 其他中东国家
• 非洲
  • 北非
  • 中非
  • 南非

第八章 竞争情势

• 热图分析
• 市占率分析
• 公司简介
  • Diadem srl.
  • Proteomedix
  • Cleveland Diagnostics
  • F. Hoffmann-La Roche Ltd
  • GENFIT
  • Nutech Cancer Biomarkers India Pvt Ltd
  • SysmOex Corporation
  • Minomic
  • Creative Diagnostics
  • Eisai Co., Ltd.
  • C2N Diagnostics

第九章

• 参考
• 分析方法
• 关于 Coherent Market Insights

Blood Based Biomarker Market is estimated to be valued at USD 8.5 Bn in 2026 and is expected to reach USD 16.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7% from 2026 to 2033.

The term biomarker, or biological marker, refers to a broad range of measures that capture what is happening in a cell or organism at a given moment. Blood-based biomarkers can be effective in formulating new diagnostic and treatment proposals. Blood-based biomarkers have significant advantages of being time and cost-efficient

Market Dynamics

Key players operating in the global blood based biomarker market are focusing on adoption of growth strategies such as product launch, collaboration, and fund raise which are expected to drive the market growth during the forecast period. For instance, in September 2020, ONCOtracker, Inc., a West Hollywood-based oncology company and The Binding Site Group Ltd, provides specialist diagnostic products to clinicians and laboratory professionals worldwide, announced they have entered into an exclusive global license and collaboration agreement to develop a novel clinical laboratory test for measuring sBCMA, a novel blood-based biomarker, which has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions. Moreover, for instance, in April 2021, Sera Prognostics, a Women's health company had secured US$100 m in Series E financing to advance the commercialization of its PreTRM test for premature birth risk. The PreTRM test is a clinically validated and commercially available blood-based biomarker test, which offers an early, precise, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.

Key features of the study

• This report provides an in-depth analysis of the Global Blood Based Biomarker Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global blood based biomarker market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Diadem srl., Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd, GENFIT, Nutech Cancer Biomarkers India Pvt Ltd, SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., and C2N Diagnostics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global blood based biomarker market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood based biomarker market

Market Segmentation

• By Type
  • Screening Biomarker
  • Diagnosis Biomarker
  • Others
• By Disease
  • Cancer
  • Neurological Disorders
  • Others
• By Application
  • Diagnostics
  • Drug Discovery
  • Personalized Medicine
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Diadem srl.
  • Proteomedix
  • Cleveland Diagnostics
  • Hoffmann-La Roche Ltd
  • GENFIT
  • Nutech Cancer Biomarkers India Pvt Ltd
  • SysmOex Corporation
  • Minomic, Creative Diagnostics, Eisai Co., Ltd.
  • C2N Diagnostics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Disease
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Blood Based Biomarkers Market, By Type, 2026 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026- 2033
  • Segment Trends
• Screening Biomarker
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Diagnosis Biomarker
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

5. Blood Based Biomarkers Market, By Disease, 2026 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

6. Blood Based Biomarkers Market, By Application, 2026 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Diagnostics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Drug Discovery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Personalized Medicine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

7. Blood Based Biomarkers Market, By Region, 2026 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Diadem srl.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Proteomedix
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Cleveland Diagnostics
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • F. Hoffmann-La Roche Ltd
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • GENFIT
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Nutech Cancer Biomarkers India Pvt Ltd
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • SysmOex Corporation
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Minomic
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Creative Diagnostics
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Eisai Co., Ltd.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • C2N Diagnostics
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us